Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Amortization of Deferred Charges: 2022-2025

Historic Amortization of Deferred Charges for Arcutis Biotherapeutics (ARQT) over the last 4 years, with Sep 2025 value amounting to $449,000.

  • Arcutis Biotherapeutics' Amortization of Deferred Charges fell 43.88% to $449,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $3.9 million, marking a year-over-year increase of 1.70%. This contributed to the annual value of $5.4 million for FY2024, which is 34.09% up from last year.
  • Latest data reveals that Arcutis Biotherapeutics reported Amortization of Deferred Charges of $449,000 as of Q3 2025, which was up 4.18% from $431,000 recorded in Q2 2025.
  • In the past 5 years, Arcutis Biotherapeutics' Amortization of Deferred Charges registered a high of $2.6 million during Q4 2024, and its lowest value of $392,000 during Q1 2022.
  • For the 3-year period, Arcutis Biotherapeutics' Amortization of Deferred Charges averaged around $975,364, with its median value being $1.0 million (2024).
  • As far as peak fluctuations go, Arcutis Biotherapeutics' Amortization of Deferred Charges surged by 155.41% in 2024, and later plummeted by 58.67% in 2025.
  • Arcutis Biotherapeutics' Amortization of Deferred Charges (Quarterly) stood at $1.0 million in 2022, then remained steady at $1.0 million in 2023, then surged by 155.41% to $2.6 million in 2024, then tumbled by 43.88% to $449,000 in 2025.
  • Its Amortization of Deferred Charges stands at $449,000 for Q3 2025, versus $431,000 for Q2 2025 and $415,000 for Q1 2025.